[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369391-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369391-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","investigation-of-an-oncolytic-herpes-simplex-virus-as-a-potential-therapeutic-agent-for-gastroenteropancreatic-neuroendocrine-neoplasms","Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms","","Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are difficult to treat due to heterogeneity and limited options. This study evaluates an engineered oncolytic herpes simplex virus (oHSV), M002, in established long-term GEP-NET cell lines and in a human pediatric patient-derived xenograft model. M002 effectively infects, replicates, and kills tumor cells in vitro, and in vivo reduces tumor growth while improving overall survival in mice. These findings support therapeutic potential and considerations for clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/investigation-of-an-oncolytic-herpes-simplex-virus-as-a-potential-therapeutic-agent-for-gastroenteropancreatic-neuroendocrine-neoplasms/369391/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/investigation-of-an-oncolytic-herpes-simplex-virus-as-a-potential-therapeutic-agent-for-gastroenteropancreatic-neuroendocrine-neoplasms/369391.png","ImageObject",300,407,{"name":42,"@type":43},"\tJames","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-17","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What challenge do gastroenteropancreatic neuroendocrine tumors present?","Question",{"text":63,"@type":64},"GEP-NETs are heterogeneous and have limited treatment options, making management complex, especially in the pediatric population.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the engineered virus M002 work in the study?",{"text":68,"@type":64},"M002 is an oncolytic herpes simplex virus engineered with deletions that prevent replication in non-cancerous cells, and it is designed to express murine interleukin to stimulate an immune response.",{"name":70,"@type":61,"acceptedAnswer":71},"What results did M002 show in vitro and in vivo?",{"text":72,"@type":64},"M002 effectively infected, replicated in, and killed GEP-NET cell lines in vitro. In mice, it decreased tumor growth and improved overall survival in models derived from both an established cell line and human PDX.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369391,1790211953,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},2336474466412,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nInvestigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms  \nColin H. Quinn1,5, Janet R. Julson1,5, Michael H. Erwin1, Hooper R. Markert1, LaruaV. Bownes1, Jerry E. Stewart1, Sorina Shirley1, Karina J. Yoon2, Jamie M. Aye3, James M. Markert4 & Elizabeth A. Beierle1􀀍  \nGastroenteropancreatic neuroendocrine tumors (GEP-NETs) present unique challenges due to their heterogeneity and limited treatment options. Oncolytic virotherapy has emerged as a promising therapeutic for other NETs and thus, we sought to investigate the potential of an engineered oncolytic herpes simplex virus (oHSV), M002, forGEP-NETS. We employed an established long-term passage GEP-NET cell line and a unique, human pediatric patient-derived xenograft GEP-NET line. We found the virus to effectively infect, replicate within, and kill both cell lines in vitro. Similar effects were noted in vivo, with M002 decreasing tumor growth and improving overall survival in mice bearing tumors from both the established cell line and human GEP-NET PDX. Overall, these studies provide an evaluation of an oncolytic HSV in GEP-NETs, highlighting its therapeutic potential and considerations for clinical translation.  \nKeywords Neuroendocrine tumors, Oncolytic virus, Patient derived xenografts, Translational research  \nCancer is the second leading cause of death in children. Extracranial solid tumors comprise about 30% of pediatric cancer types. Neuroendocrine tumors (NETs) are solid tumors of neural crest origin, and given the ubiquitous nature of the neuroendocrine system, NETs manifest in nearly every compartment of the body. Gastroenteropancreatic (GEP)-NETs are a subtype of NETs that arise from the gastrointestinal tract or pancreas. These tumors are rare in the pediatric population, having a reported incidence of 0.1 per million, but this incidence has been steadily increasing without a proportional change in overall survival1–3.  \nThe management of pediatric GEPNETs is complex. Complete surgical resection is often curative, but due to the indolent nature of GEP-NETs, at least 10% of pediatric patients present with metastases at diagnosis4,5. Further, there are at least 13 different neuroendocrine cell types that occur within the gastrointestinal tract, making this rare tumor type even more heterogeneous and difficult to manage6. Non-surgical treatment options include somatostatin analogs7, targeted molecular therapies8,9, including tyrosine kinase inhibitors or anti-angiogenic agents, cytotoxic chemotherapy10, 11, or peptide receptor radionuclide therapy12, 13. Current survival rates for children with GEP-NETs are reported at less than 41%, highlighting the need for more effective therapeutic strategies14.  \nOncolytic viruses offer an innovative approach to cancer therapy. The anti-cancer effect of oncolytic viruses is two-fold: (i) tumor cell cytolysis by viral infection and replication, and (ii) creation of an immunoreactive debris field to attract and activate cytotoxic immune cells. M002 is an oncolytic herpes simplex virus (oHSV) that has been genetically engineered with a deletion in both copies of the γ134.5 gene that prevents its ability to replicate in non-cancerous cells15. In addition, M002 is uniquely designed to express murine interleukin (mIL-12) thereby  \n1Division of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, 1600 7thAve South, Lowder, Suite 300, Birmingham, AL 35233, USA. 2Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, USA. 3Division of Hematology Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA. 4Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA. 5These authors contributed equally: Colin H. Quinn and Janet R. Julson. 􀀍 email:","cbCair6o4pHXAzaG","https://ap.wps.com/l/cbCair6o4pHXAzaG","pdf",1516452,"English","# Introduction\n# Oncolytic virotherapy rationale\n# Methods\n## Cell lines and culture","[{\"question\":\"What challenge do gastroenteropancreatic neuroendocrine tumors present?\",\"answer\":\"GEP-NETs are heterogeneous and have limited treatment options, making management complex, especially in the pediatric population.\"},{\"question\":\"How does the engineered virus M002 work in the study?\",\"answer\":\"M002 is an oncolytic herpes simplex virus engineered with deletions that prevent replication in non-cancerous cells, and it is designed to express murine interleukin to stimulate an immune response.\"},{\"question\":\"What results did M002 show in vitro and in vivo?\",\"answer\":\"M002 effectively infected, replicated in, and killed GEP-NET cell lines in vitro. In mice, it decreased tumor growth and improved overall survival in models derived from both an established cell line and human PDX.\"}]","Investigation of an oncolytic herpes simplex virus as a potential therapeutic agent for gastroenteropancreatic neuroendocrine neoplasms | PDF",1790182392,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6aedd2579e30a211bf8ef65577c4f466.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c80ca52e15670d9de7558c6acd5fcfee.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d6b2cd43dbcae4d4336164ed270525e9.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f407ca93ea9559c19955905f987ca37a.webp",980,1287]